Automate Your Wheel Strategy on DHR
With Tiblio's Option Bot, you can configure your own wheel strategy including DHR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DHR
- Rev/Share 33.5143
- Book/Share 73.0412
- PB 2.7928
- Debt/Equity 0.3316
- CurrentRatio 1.6194
- ROIC 0.0491
- MktCap 146067447480.0
- FreeCF/Share 6.7858
- PFCF 30.0427
- PE 42.8242
- Debt/Assets 0.2126
- DivYield 0.0058
- ROE 0.0669
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | DHR | Scotiabank | Sector Perform | Sector Outperform | -- | $275 | July 11, 2025 |
| Upgrade | DHR | Barclays | Equal Weight | Overweight | -- | $205 | April 10, 2025 |
| Upgrade | DHR | Goldman | Neutral | Buy | -- | $260 | March 21, 2025 |
| Upgrade | DHR | Stifel | Hold | Buy | -- | $260 | March 14, 2025 |
| Downgrade | DHR | Raymond James | Outperform | Market Perform | -- | -- | Feb. 3, 2025 |
| Initiation | DHR | Scotiabank | -- | Sector Perform | -- | -- | Dec. 23, 2024 |
| Initiation | DHR | Guggenheim | -- | Buy | -- | $275 | Dec. 19, 2024 |
| Upgrade | DHR | BofA Securities | Neutral | Buy | -- | $290 | Dec. 13, 2024 |
| Initiation | DHR | Stephens | -- | Overweight | -- | $315 | Oct. 1, 2024 |
| Initiation | DHR | Wells Fargo | -- | Equal Weight | -- | $280 | Aug. 28, 2024 |
News
International Markets and Danaher (DHR): A Deep Dive for Investors
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Read More
Danaher Q2 2025 Update
Published: July 24, 2025 by: Seeking Alpha
Sentiment: Negative
While the worst seem to be behind them, the business isn't quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year adjusted diluted net EPS guidance to a range of $7.70 to $7.80 vs previous range of $7.60 to $7.75. Compared to the past few years, Danaher's multiples have noticeably come down. However, it is hard for a stock to go up if revenue growth hovers around LSD level.
Read More
CVS or DHR: Which Is the Better Value Stock Right Now?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical Services stocks are likely familiar with CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Read More
Here's Why Danaher (DHR) is a Strong Growth Stock
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Danaher Stock: Attractively Valued And Poised For Growth Acceleration
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Positive
Danaher Corporation is returning to growth, led by strong bioprocessing demand and resilient diagnostics, with Life Sciences expected to recover in late 2025. Margins may face short-term pressure, but a $150M cost-reduction plan and easing China headwinds should drive margin expansion from FY26 onward. The stock trades at a meaningful discount to historical valuation, offering compelling upside as earnings growth is set to reaccelerate post-FY25.
Read More
Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Danaher Corporation (NYSE:DHR ) Q2 2025 Earnings Conference Call July 22, 2025 8:00 AM ET Company Participants John Bedford - Vice President of Investor Relations Matthew R. McGrew - CFO & Executive VP Rainer M.
Read More
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Read More
Danaher (DHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.
Read More
45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive
I analyze Barron's Mid-Year 2025 Roundtable Pro Picks using the yield-based 'dogcatcher' method to identify high-yield, safer dividend stocks. AT&T, Tegna, and Pitney Bowes stand out as 'safer' dividend dogs, with prices below annual dividends from $1,000 invested, signaling attractive entry points. The top ten high-yield picks offer projected 24.3% average net gains by July 2026, with lower-than-market volatility, but some face negative free cash flow margins.
Read More
CVS vs. DHR: Which Stock Is the Better Value Option?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why Danaher (DHR) is a Top Growth Stock for the Long-Term
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Danaher: High Capex And Low Debt Despite Trump Legislation
Published: June 19, 2025 by: Seeking Alpha
Sentiment: Positive
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Between 2017 and 2024, Danaher invested 25.81% of its revenues to expand its operations, which has contributed to the growth rate of its revenues.
Read More
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Read More
Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--SCIEX announces three software ecosystem enhancements at ASMS, supporting the theme that “all science is data science now.”.
Read More
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ZenoTOF--At ASMS 2025, SCIEX launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation.
Read More
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Evocep--SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement.
Read More
Danaher Partners With AstraZeneca to Support Precision Medicine
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Read More
CVS or DHR: Which Is the Better Value Stock Right Now?
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Read More
Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Read More
Here's Why Investors Should Consider Retaining Danaher Stock Now
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
Read More
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Danaher Corporation (NYSE:DHR ) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team and I'm excited to host our next session.
Read More
CVS vs. DHR: Which Stock Is the Better Value Option?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
Danaher Corporation's intrinsic value is estimated at $213 per share, suggesting a 14% upside from the current price of $187, with a 12% margin of safety. Despite revenue growth driven by acquisitions, Danaher's heavy reliance on debt and declining ROIC indicate challenges in capital efficiency and operational performance. The company's high capital intensity, slow growth, and mounting debt levels make its near-term investment potential pessimistic, despite a diversified portfolio.
Read More
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Read More
BLCO or DHR: Which Is the Better Value Stock Right Now?
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Read More
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Danaher Reports First Quarter 2025 Results
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
WASHINGTON , April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.
Read More
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
Read More
About Danaher Corporation (DHR)
- IPO Date 1978-12-29
- Website https://www.danaher.com
- Industry Medical - Diagnostics & Research
- CEO Rainer M. Blair
- Employees 61000